UPSHER-SMITH PREVIEWS EXPANSION OF ITS RARE DISEASE PORTFOLIO AT 2024 AAN ANNUAL MEETING

StreetInsider04-12

Discover the Company's Promise of Support™ Program at Booth #818 MAPLE GROVE, Minn., April 12, 2024 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2426734442?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-12 23:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2426734442","market":"us","top_or_hot":-1,"title":"UPSHER-SMITH PREVIEWS EXPANSION OF ITS RARE DISEASE PORTFOLIO AT 2024 AAN ANNUAL MEETING","media":"StreetInsider","content":"<div>\n<p>Discover the Company's Promise of Support™ Program at Booth #818\nMAPLE GROVE, Minn., April 12, 2024 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=23060708\">Source Link</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPSHER-SMITH PREVIEWS EXPANSION OF ITS RARE DISEASE PORTFOLIO AT 2024 AAN ANNUAL MEETING</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPSHER-SMITH PREVIEWS EXPANSION OF ITS RARE DISEASE PORTFOLIO AT 2024 AAN ANNUAL MEETING\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-12 23:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=23060708><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Discover the Company's Promise of Support™ Program at Booth #818\nMAPLE GROVE, Minn., April 12, 2024 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=23060708\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RARE","symbol_name":"Ultragenyx Pharmaceutical Inc","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=23060708","article_id":"2426734442","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2426734442","pubTimestamp":1712937060,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"Discover the Company's Promise of Support Program at Booth #818. MAPLE GROVE, Minn., April 12, 2024 /PRNewswire/ -- Upsher-Smith Laboratories, LLC  today announced that it will be participating in the 2024 American Academy of Neurology  Annual Meeting in Denver, from April 13 to 18, 2024. Representatives from Upsher-Smith will be on hand at Booth #818 to showcase its expanding portfolio of medications backed by the Promise of Support Program, including the VIGADRONE  product family and TORPENZ  Tablets slated for availability in mid-2024.Since the successful launch of VIGADRONE  for Oral Solution, USP 500 mg to the specialty pharmacy channel in 2018, Upsher-Smith has broadened its offerings to include VIGADRONE  Tablets, USP 500 mg. TORPENZ Tablets, a branded-generic everolimus tablet, will soon be available to prescribers and patients.","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"RARE":"Ultragenyx Pharmaceutical Inc","BK4139":"生物科技","VIRI":"Virios Therapeutics, LLC","BK4124":"机动车零配件与设备","BK4178":"家庭装饰零售","BK4097":"系统软件","IS":"IronSource Ltd","CPS":"Cooper-Standard Holdings Inc.","AAN":"The Aaron's Company, Inc."},"translate_title":"UPSHER-SMITH在2024年AAN年会上预览其罕见病产品组合的扩展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AAN":1,"CPS":1,"IS":1,"RARE":1,"VIRI":0.68},"content_text":"Discover the Company's Promise of Support™ Program at Booth #818\nMAPLE GROVE, Minn., April 12, 2024 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be participating in the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, from April 13 to 18, 2024. Representatives from Upsher-Smith will be on hand at Booth #818 to showcase its expanding portfolio of medications backed by the Promise of Support™ Program, including the VIGADRONE® (vigabatrin) product family and TORPENZ™ (everolimus) Tablets slated for availability in mid-2024.\n\n\n\n\n\nSince the successful launch of VIGADRONE® (vigabatrin) for Oral Solution, USP 500 mg to the specialty pharmacy channel in 2018, Upsher-Smith has broadened its offerings to include VIGADRONE® (vigabatrin) Tablets, USP 500 mg. TORPENZ™ Tablets, a branded-generic everolimus tablet, will soon be available to prescribers and patients.\nCentral to Upsher-Smith's commitment to rare disease communities is its Promise of Support™ Program, ensuring comprehensive assistance for patients, caregivers, and healthcare providers throughout the treatment journey. For more than five years, the program has offered resources for uninterrupted medication supply, prior authorization support, copay and patient assistance, patient education materials, collaboration with a leading specialty pharmacy partner, and streamlined prescribing and enrollment procedures.\nRich Fisher, President and COO of Upsher-Smith emphasized the company's dedication to improving access and affordability to its products while prioritizing unparalleled service and support. \"We understand the challenges faced by families battling rare diseases, and our team is steadfast in delivering solutions that ease some of the burden for patients and their families. We eagerly anticipate previewing our new everolimus option at this year's American Academy of Neurology Annual Meeting and engaging attendees in discussions about the benefits of our Promise of Support™ Program.\"\nTo learn more about Upsher-Smith's Promise of Support™ Program for the VIGADRONE® family of products, visit VIGADRONE.com, and to stay updated on TORPENZ™ (everolimus) Tablets, visit www.torpenz.com/availability.\nPlease see Important Safety Information, including Boxed Warning for Risk of Permanent Vision Loss at the end of this communication.\nVIGADRONE® (vigabatrin) is a prescription medicine used to treat:\nInfantile Spasms (IS) in patients 1 month to 2 years of age, if you and your healthcare provider decide the possible benefits of taking VIGADRONE are more important than the possible risk of vision loss.Refractory Complex Partial Seizures (CPS) in adults and children 2 years and older with refractory complex partial seizures (CPS) along with other treatments if:The CPS do not respond well enough to several other treatments, andYou and your healthcare provider decide the possible benefit of taking VIGADRONE is more important than the risk of vision loss.VIGADRONE should not be the first medicine used to treat CPS.\nWHAT IMPORTANT SAFETY INFORMATION SHOULD I KNOW ABOUT VIGADRONE® (vigabatrin)?\nWARNING: PERMANENT VISION LOSS\nSee Medication Guide and full Prescribing Information for complete information.\nAll people who take VIGADRONE:\n•\nYou are at risk for permanent vision loss with any amount of VIGADRONE.\n•\nYour risk of vision loss may be higher the more VIGADRONE you take daily and the longer you take it. \n•\nIt is not possible for your healthcare provider to know when vision loss will happen. It could happen soon after starting VIGADRONE or any time during treatment. It may even happen after treatment has stopped. \nBecause VIGADRONE might cause permanent vision loss, it is available to healthcare providers and patients only under a special program called the Vigabatrin Risk Evaluation and Mitigation Strategy (REMS) Program. Your healthcare provider will explain the details of this Program to you.VIGADRONE can damage the vision of anyone who takes it. Some people can have severe loss, particularly to their ability to see to the side when looking straight ahead (peripheral vision). With severe vision loss, you may only be able to see things straight in front of you (sometimes called \"tunnel vision\"). You may also have blurry vision. If this happens, it will not get better.Tell your healthcare provider right away if you (or your child): might not be seeing as well as before starting VIGADRONE; start to trip, bump into things, or are more clumsy than usual; are surprised by people or things coming in front of you that seem to come out of nowhere; or if your baby is acting differently than normal. These changes can mean that vision damage has occurred.Regular vision testing is recommended. It is recommended that your healthcare provider test your (or your child's) vision before or within 4 weeks after starting VIGADRONE, and at least every 3 months during treatment until VIGADRONE is stopped. It is also recommended that vision be tested about 3 to 6 months after VIGADRONE is stopped. It is difficult to test vision in babies, but to the extent possible, all patients should have their vision tested. Your healthcare provider will determine if testing can be done. Regular vision testing is important because damage can happen before any changes are noticed.Vision tests cannot prevent the vision damage that can happen with VIGADRONE, but they do allow VIGADRONE to be stopped if vision has gotten worse, which usually will lessen further damage. Even these regular vision tests may not show vision damage before it is serious and permanent. Parents, caregivers, and healthcare providers may not recognize the symptoms, or find vision loss in patients, until it is severe.If you do not have these vision tests regularly, your healthcare provider may stop prescribing VIGADRONE for you (or your child). Some people are not able to complete vision testing. If vision testing cannot be done, your healthcare provider may continue prescribing VIGADRONE, but will not be able to watch for any vision loss.Magnetic resonance imaging (MRI) changes in patients with infantile spasms (IS). Brain pictures taken by MRI show changes in some patients after they are given VIGADRONE. It is not known if these changes are harmful.A type of swelling in the brain called intramyelinic edema (IME) has been seen in autopsy examination of patients treated with vigabatrin.Risk of suicidal thoughts or actions. Like other antiepileptic drugs, VIGADRONE may cause suicidal thoughts and actions in some people (about 1 in 500 people). Call a healthcare provider right away if you (or your child) have any symptoms, especially sudden changes in mood, behaviors, thoughts or feelings, and especially if they are new, worse, or worry you.Do not stop VIGADRONE without first talking to a healthcare provider. Stopping VIGADRONE suddenly can cause seizures that will not stop.VIGADRONE can cause serious side effects such as low red blood cell counts (anemia), sleepiness and tiredness, nerve problems, weight gain, and swelling. Because VIGADRONE causes sleepiness and tiredness, do not drive, operate machinery, or perform any hazardous task, unless it is decided that these things can be done safely. VIGADRONE may make certain types of seizures worse. Tell your healthcare provider right away if seizures get worse.\nBefore starting VIGADRONE, tell your doctor about all of your (or your child's) medical conditions including depression, mood problems, suicidal thoughts or behavior, any allergic reaction to VIGADRONE, vision problems, kidney problems, low red blood cell counts (anemia), and any nervous or mental illnesses. Tell your doctor about all the medicines you (or your child) take.\nIf you are breastfeeding or plan to breastfeed, VIGADRONE can pass into breast milk and may harm your baby. Breastfeeding is not recommended.\nIf you are pregnant or plan to become pregnant, VIGADRONE can cause harm to your unborn baby. You and your healthcare provider will have to decide if you should take VIGADRONE while you are pregnant.\nThe most common side effects of VIGADRONE in adults include: blurred vision, sleepiness, dizziness, problems walking or feeling uncoordinated, shaking (tremor) and tiredness.\nThe most common side effect of VIGADRONE in children 3 to 16 years of age is weight gain. Also expect side effects like those seen in adults.\nThe most common side effects of VIGADRONE in babies include: sleepiness (sleepy babies may have a harder time suckling and feeding or may be irritable), swelling in the bronchial tubes (bronchitis), ear infection and irritability.\nTell your healthcare provider if you or your child have any side effect that bothers you or that does not go away. \nThis is the most important information to know about VIGADRONE, but it is not all the safety information. For more information, ask your healthcare provider or pharmacist, or please see the VIGADRONE Medication Guide, full Prescribing Information including Boxed Warning for risk of permanent vision loss, and Instructions for Use. You can also visit vigadrone.com, upsher-smith.com or call 1-888-650-3789.\nYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-332-1088.\nAbout Upsher-Smith\nUpsher-Smith Laboratories, LLC, now a member of Bora Group, is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. We bring generics and brands to a wide array of customers, always backed by our attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit www.upsher-smith.com.\nAbout Bora\nFounded in 2007, Bora Pharmaceutical Co., Ltd. (\"Bora\" or \"the Company\", 6472.TW) now is the largest pharmaceutical manufacturer in Taiwan with well-connected global distribution to supply more than 100 countries around the world. Headquartered in Taiwan, Bora has dedicated itself to becoming a global leader in pharmaceutical manufacturing by offering its clients the best quality, efficiency and reliability.\nVIGADRONE, TORPENZ, and PROMISE OF SUPPORT are trademarks of Upsher-Smith Laboratories, LLC.\n View original content to download multimedia:https://www.prnewswire.com/news-releases/upsher-smith-previews-expansion-of-its-rare-disease-portfolio-at-2024-aan-annual-meeting-302115529.html\nSOURCE Upsher-Smith Laboratories, LLC","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426734442"}